AbbVie (ABBV) Stock Forecast & Price Target

AbbVie has demonstrated robust growth potential, with management forecasting global sales in the Neuroscience segment to reach approximately $10.7 billion by 2025, reflecting a modest upward revision from earlier estimates driven by key products like Vyalev and Botox Therapeutic. The company has also raised its FY 2025 earnings per share guidance to a range of $12.09 to $12.29, an increase of 10 cents at the midpoint, alongside a revenue forecast adjustment to roughly $59.7 billion, indicating strong overall commercial performance. Furthermore, AbbVie's strong quarterly sales of $13.34 billion in Q1 2025 surpassed both expectations and consensus, largely attributed to the success of its immunology and oncology franchises, including Skyrizi and Rinvoq, which positions the company favorably for sustained growth.

AbbVie faces significant downside risks, including potential disappointing commercial execution on key products such as Skyrizi, Rinvoq, and Botox, which could hinder revenue growth. The anticipated erosion of Humira sales due to increased competition from biosimilars and limited market penetration of newer products further complicates the company's long-term guidance expectations. Additionally, macroeconomic pressures, particularly affecting the Aesthetics business and pipeline developments, raise concerns about expected revenue and earnings, as demonstrated by increased operational costs that negatively impacted recent earnings per share results.